Omega Healthcare Investors (OHI)
(Delayed Data from NYSE)
$30.26 USD
-0.16 (-0.53%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $30.26 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Omega Healthcare Investors (OHI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$32.83 | $36.00 | $28.00 | 7.92% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Omega Healthcare Investors comes to $32.83. The forecasts range from a low of $28.00 to a high of $36.00. The average price target represents an increase of 7.92% from the last closing price of $30.42.
Analyst Price Targets (15)
Broker Rating
Omega Healthcare Investors currently has an average brokerage recommendation (ABR) of 2.31 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 2.31 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 31.25% and 6.25% of all recommendations. A month ago, Strong Buy made up 31.25%, while Buy represented 6.25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 4 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 10 | 10 | 10 | 12 | 11 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 1 |
ABR | 2.31 | 2.31 | 2.31 | 2.47 | 2.69 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/1/2024 | Truist Securities | Michael Lewis | Hold | Hold |
3/20/2024 | Scotiabank | Nicholas Yulico | Hold | Hold |
2/8/2024 | Exane BNP Paribas | Nathan D Crossett | Strong Sell | Hold |
1/3/2024 | Mizuho SecuritiesUSA | Vikram Malhotra | Strong Buy | Strong Buy |
1/2/2024 | Robert W. Baird & Co. | Wesley Golladay | Hold | Hold |
11/5/2023 | JMP Securities | Aaron Hecht | Not Available | Hold |
10/3/2023 | Wedbush Securities | Richard Anderson | Hold | Hold |
9/20/2023 | Raymond James | Jonathan Hughes | Moderate Buy | Moderate Buy |
7/27/2023 | BMO Capital Markets | Juan Sanabria | Not Available | Hold |
7/27/2023 | Berenberg Bank | Tammy Qiu | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.31 |
ABR (Last week) | 2.31 |
# of Recs in ABR | 16 |
Average Target Price | $32.83 |
LT Growth Rate | 1.20% |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | 0.65 |